Pramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline

Pramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline

VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Pramana Pharmaceuticals, a late-stage preclinical biopharmaceutical company developing a transformative small molecule platform targeting the intersection of metabolism, immunity, and neurodegeneration, today announced the appointment of Adrian Noriega, M.D., Ph.D., to…

Cambridge and Peterborough trial for blood tests to diagnose dementia welcomes first participants - Essex Magazine

A groundbreaking trial exploring the potential of blood tests to diagnose dementia is now underway in Cambridgeshire and Peterborough, marking a significant step toward improving the UK’s dementia diagnosis rate. This initiative, led by the READ-OUT research team at Dementias Platform UK (DPUK), seeks to address gaps in diagnosis and enhance early detection of dementia, […]

Oral PRI-002 Trial Shows Promise for Early Alzheimer’s

In a landmark advancement in neurodegenerative disease therapeutics, researchers have unveiled promising results from a randomized, double-blind phase 1b clinical trial evaluating the efficacy and safety of oral PRI-002 treatment in patients diagnosed with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). This pioneering study, recently published in Nature Communications, offers an insightful glimpse into a potential novel interv…